

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

SHARE AWARD SCHEME
INCREASE OF SCHEME LIMIT

Reference is made to the announcement of Kingworld Medicines Group Limited (the “**Company**”) dated 27 August 2019 (the “**Announcement**”) in relation to the adoption of the share award scheme (the “**Share Award Scheme**”) by the Company and the announcement of the Company dated 22 May 2020 in relation to the increase of scheme limit (the “**First Increased Scheme Limit**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

INCREASE OF SCHEME LIMIT

As disclosed in the Announcement, the purposes of the Share Award Scheme are to recognise the contributions by certain Participants and to provide incentives in retaining the Participants for the continual operation and development of the Group and to attract suitable personnel for further development of the Group.

Pursuant to the Share Award Scheme and the First Increased Scheme Limit, the Board shall not make any further Award which will result in the total number of the Awarded Shares under the Share Award Scheme to be in excess of 16,000,000 Shares (the “**Scheme Limit**”) (subject to adjustment in the event of sub-division of Shares, consolidation of Shares or bonus issue in accordance with the Award Scheme Rules) unless otherwise determined by the resolution of the Board.

In order to provide further incentives for the Participants, the Board is pleased to announce that it has resolved to further increase the Scheme Limit to 46,000,000 Shares (being approximately 7.39% of the issued share capital of the Company as at the date of this announcement) (the “**Second Increased Scheme Limit**”) (subject to adjustment in the event of sub-division of Shares, consolidation of Shares or bonus issue in accordance with the Award Scheme Rules) with effect from 13 July 2022.

Apart from the Second Increased Scheme Limit, there is no change on the Share Award Scheme.

The Board will from time to time review and determine at its absolute discretion such number of Shares to be awarded to the Selected Participants with such vesting conditions as it may deem appropriate and the number of Shares to be purchased by the Trustee from the market under the Share Award Scheme.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 13 July 2022

As at the date of this announcement, the executive Directors are Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and the independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.